BR112014012409A2 - composições de buprenorfina e antagonistas do receptor mu-opiódie - Google Patents

composições de buprenorfina e antagonistas do receptor mu-opiódie

Info

Publication number: BR112014012409A2
Authority: BR; Brazil
Prior art keywords: receptor antagonists; opioid receptor; buprenorphine compositions; buprenorphine; compositions
Prior art date: 2011-12-15

Application number

BR112014012409A

Other languages

English (en)

Other versions

BR112014012409B8 (pt

BR112014012409B1 (pt

Inventor

Deaver Daniel

Ehrich Elliot

Original Assignee

Alkermes Pharma Ireland Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-15

Filing date

2012-12-14

Publication date

2017-06-13

2012-12-14 Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd

2017-06-13 Publication of BR112014012409A2 publication Critical patent/BR112014012409A2/pt

2022-08-23 Publication of BR112014012409B1 publication Critical patent/BR112014012409B1/pt

2022-09-13 Publication of BR112014012409B8 publication Critical patent/BR112014012409B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BR112014012409A 2011-12-15 2012-12-14 Composições de buprenorfina e antagonistas do receptor mu-opioide BR112014012409B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161576233P	2011-12-15	2011-12-15
US61/576,233		2011-12-15
PCT/IB2012/002900 WO2013088243A1 (en)	2011-12-15	2012-12-14	Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (3)

Publication Number	Publication Date
BR112014012409A2 true BR112014012409A2 (pt)	2017-06-13
BR112014012409B1 BR112014012409B1 (pt)	2022-08-23
BR112014012409B8 BR112014012409B8 (pt)	2022-09-13

Family

ID=47757653

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112014012409A BR112014012409B8 (pt)	2011-12-15	2012-12-14	Composições de buprenorfina e antagonistas do receptor mu-opioide

Country Status (25)

Country	Link
US (8)	US8822488B2 (pt)
EP (3)	EP3415148A1 (pt)
JP (2)	JP6038170B2 (pt)
KR (1)	KR101996108B1 (pt)
CN (2)	CN104159586A (pt)
AU (1)	AU2012351806C1 (pt)
BR (1)	BR112014012409B8 (pt)
CA (1)	CA2858812C (pt)
CY (1)	CY1121081T1 (pt)
DK (1)	DK3153171T3 (pt)
EA (1)	EA030609B8 (pt)
ES (2)	ES2692771T3 (pt)
HR (1)	HRP20181950T1 (pt)
HU (1)	HUE041883T2 (pt)
IL (1)	IL232785B (pt)
LT (1)	LT3153171T (pt)
MX (2)	MX391181B (pt)
PL (1)	PL3153171T3 (pt)
PT (1)	PT3153171T (pt)
RS (1)	RS58322B1 (pt)
SI (1)	SI3153171T1 (pt)
SM (1)	SMT201800664T1 (pt)
TR (1)	TR201815154T4 (pt)
WO (1)	WO2013088243A1 (pt)
ZA (1)	ZA201405029B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5691042B2 (ja)	2009-12-04	2015-04-01	アルカーメスファーマアイルランドリミテッド	薬物過量摂取の治療のためのモルヒナン誘導体
DK3446565T3 (da)	2010-08-23	2024-01-22	Alkermes Pharma Ireland Ltd	Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
EA030609B8 (ru)	2011-12-15	2018-10-31	Алкермес Фарма Айэленд Лимитед	Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
US9211293B2 (en)	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
US9656961B2 (en)	2013-05-24	2017-05-23	Alkermes Pharma Ireland Limited	Methods for treating depressive symptoms
US9133125B2 (en)	2013-05-24	2015-09-15	Alkermes Pharma Ireland Limited	Morphan and morphinan analogues, and methods of use
TW201636329A (zh)	2015-02-02	2016-10-16	佛瑪治療公司	作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
IL280856B (en)	2015-02-02	2022-09-01	Forma Therapeutics Inc	3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP3472131B1 (en)	2016-06-17	2020-02-19	Forma Therapeutics, Inc.	2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2022101444A1 (en)	2020-11-12	2022-05-19	Alkermes Pharma Ireland Limited	Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH581624A5 (pt)	1970-08-14	1976-11-15	Sumitomo Chemical Co
US3856795A (en)	1972-04-25	1974-12-24	American Home Prod	Process for preparation of secondary amines from tertiary amines
US3957793A (en)	1974-09-20	1976-05-18	Sterling Drug Inc.	Hydroxyiminobenzazocines
US4032529A (en)	1974-09-20	1977-06-28	Sterling Drug Inc.	Aminomethanobenzazocine intermediates
US4127577A (en)	1975-11-24	1978-11-28	Sterling Drug Inc.	Aminomethanobenzazocine process
US4205171A (en)	1976-01-12	1980-05-27	Sterling Drug Inc.	Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en)	1981-04-28	1984-08-07	University Of Kentucky Research Foundation	Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) *	1983-12-06	1984-01-11	Reckitt & Colmann Prod Ltd	Analgesic compositions
US4649200A (en)	1986-05-08	1987-03-10	Regents Of The University Of Minnesota	Substituted pyrroles with opioid receptor activity
US4939264A (en)	1986-07-14	1990-07-03	Abbott Laboratories	Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en)	1991-06-05	1993-11-02	The United States Of America As Represented By The Secretary Of The Army	(+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en)	1992-06-26	1997-03-04	Boehringer Ingelheim Kg	Useful for treating neurodegenerative diseases
SE9103745D0 (sv)	1991-12-18	1991-12-18	Wikstroem Haakan	Aryl-triflates and related compounds
EP0632041A1 (en)	1993-07-01	1995-01-04	Katholieke Universiteit Nijmegen	New morphine derivatives having improved analgesic and narcotic properties
HUP9900974A3 (en)	1996-01-10	2000-09-28	Smithkline Beecham Spa	Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
GB9709972D0 (en)	1997-05-19	1997-07-09	Pfizer Ltd	Tetrazoles
US7534866B2 (en) *	2005-10-19	2009-05-19	Ibc Pharmaceuticals, Inc.	Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en)	1999-05-28	1999-07-28	Pfizer Ltd	Compounds useful in therapy
ES2572332T3 (es)	2000-10-31	2016-05-31	Rensselaer Polytech Inst	2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
ES2305457T3 (es) *	2002-03-20	2008-11-01	Euro-Celtique S.A.	Metodo de administracion de buprenorfina para tratar la depresion.
ES2249722T3 (es)	2002-05-30	2006-04-01	Eli Lilly And Company	Antagonistas de receptor de opioides.
BRPI0511137A (pt)	2004-05-14	2007-11-27	Janssen Pharmaceutica Nv	compostos opióides de carboxamido
US20060063792A1 (en)	2004-09-17	2006-03-23	Adolor Corporation	Substituted morphinans and methods of their use
CA2587074C (en)	2004-11-05	2012-09-04	Rensselaer Polytechnic Institute	4-hydroxybenzomorphans
PT1856093E (pt)	2005-03-02	2010-02-08	Nycomed Gmbh	Sal hcl de (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-etoxi- 8-metoxi-1,2,3,4,4a,10b-hexa-hidrofenantridin-2-ol
CN101677971A (zh)	2007-03-19	2010-03-24	阿卡蒂亚药品公司	5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
CA2694497C (en)	2007-08-09	2016-07-12	Rensselaer Polytechnic Institute	Quaternary opioid carboxamides
EP2252150B1 (en) *	2008-02-14	2018-04-11	Alkermes, Inc.	Selective opioid compounds
WO2009126931A2 (en) *	2008-04-11	2009-10-15	Xvasive, Inc.	Combination therapy for bipolar disorder
WO2010107457A1 (en) *	2009-03-19	2010-09-23	Alkermes, Inc.	Morphinan derivatives with high oral bioavailability
US20120149724A1 (en)	2009-06-04	2012-06-14	The General Hospital Corporation	Modulating endogenous beta-endorphin levels
US8530479B2 (en) *	2009-08-10	2013-09-10	Daljit Singh Dhanoa	Deuterium-enriched alkyl sulfonamides
JP5691042B2 (ja) *	2009-12-04	2015-04-01	アルカーメスファーマアイルランドリミテッド	薬物過量摂取の治療のためのモルヒナン誘導体
US9211293B2 (en) *	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
EA030609B8 (ru)	2011-12-15	2018-10-31	Алкермес Фарма Айэленд Лимитед	Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
US9656961B2 (en) *	2013-05-24	2017-05-23	Alkermes Pharma Ireland Limited	Methods for treating depressive symptoms

2012
- 2012-12-14 EA EA201491153A patent/EA030609B8/ru unknown
- 2012-12-14 CN CN201280062291.6A patent/CN104159586A/zh active Pending
- 2012-12-14 BR BR112014012409A patent/BR112014012409B8/pt not_active IP Right Cessation
- 2012-12-14 SM SM20180664T patent/SMT201800664T1/it unknown
- 2012-12-14 DK DK16201359.3T patent/DK3153171T3/en active
- 2012-12-14 SI SI201231474T patent/SI3153171T1/sl unknown
- 2012-12-14 WO PCT/IB2012/002900 patent/WO2013088243A1/en active Application Filing
- 2012-12-14 KR KR1020147016224A patent/KR101996108B1/ko not_active Expired - Fee Related
- 2012-12-14 JP JP2014546667A patent/JP6038170B2/ja not_active Expired - Fee Related
- 2012-12-14 PT PT16201359T patent/PT3153171T/pt unknown
- 2012-12-14 EP EP18187096.5A patent/EP3415148A1/en not_active Withdrawn
- 2012-12-14 MX MX2020000270A patent/MX391181B/es unknown
- 2012-12-14 ES ES16201359.3T patent/ES2692771T3/es active Active
- 2012-12-14 HU HUE16201359A patent/HUE041883T2/hu unknown
- 2012-12-14 EP EP12830900.2A patent/EP2790702B1/en active Active
- 2012-12-14 TR TR2018/15154T patent/TR201815154T4/tr unknown
- 2012-12-14 PL PL16201359T patent/PL3153171T3/pl unknown
- 2012-12-14 CN CN201611052441.1A patent/CN106727562B/zh not_active Expired - Fee Related
- 2012-12-14 EP EP16201359.3A patent/EP3153171B1/en active Active
- 2012-12-14 CA CA2858812A patent/CA2858812C/en active Active
- 2012-12-14 LT LTEP16201359.3T patent/LT3153171T/lt unknown
- 2012-12-14 RS RS20181543A patent/RS58322B1/sr unknown
- 2012-12-14 US US13/715,198 patent/US8822488B2/en active Active
- 2012-12-14 AU AU2012351806A patent/AU2012351806C1/en not_active Ceased
- 2012-12-14 MX MX2014007042A patent/MX375348B/es active IP Right Grant
- 2012-12-14 ES ES12830900T patent/ES2791764T3/es active Active
2014
- 2014-05-25 IL IL232785A patent/IL232785B/en active IP Right Grant
- 2014-07-10 ZA ZA2014/05029A patent/ZA201405029B/en unknown
- 2014-07-29 US US14/445,407 patent/US9498474B2/en active Active
2016
- 2016-03-10 US US15/066,567 patent/US9918978B2/en active Active
- 2016-07-29 JP JP2016150353A patent/JP6403726B2/ja not_active Expired - Fee Related
- 2016-09-12 US US15/262,628 patent/US9913837B2/en active Active
2017
- 2017-09-28 US US15/718,139 patent/US10314838B2/en active Active
- 2017-10-02 US US15/722,408 patent/US10188643B2/en active Active
2018
- 2018-11-22 HR HRP20181950TT patent/HRP20181950T1/hr unknown
- 2018-12-18 CY CY181101356T patent/CY1121081T1/el unknown
2019
- 2019-04-25 US US16/394,524 patent/US10806731B2/en active Active
2020
- 2020-10-06 US US17/063,892 patent/US20210196703A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN104159586A (zh)	2014-11-19
EP3153171B1 (en)	2018-09-19
DK3153171T3 (en)	2018-11-19
EP3153171A1 (en)	2017-04-12
MX391181B (es)	2025-03-21
TR201815154T4 (tr)	2018-11-21
JP2015505853A (ja)	2015-02-26
RS58322B1 (sr)	2019-03-29
CY1121081T1 (el)	2019-12-11
JP2016222706A (ja)	2016-12-28
JP6403726B2 (ja)	2018-10-10
MX2014007042A (es)	2015-01-22
US20170056392A1 (en)	2017-03-02
CN106727562A (zh)	2017-05-31
MX375348B (es)	2025-03-06
BR112014012409B8 (pt)	2022-09-13
US20180078543A1 (en)	2018-03-22
AU2012351806B2 (en)	2016-03-10
SI3153171T1 (sl)	2019-01-31
CA2858812C (en)	2019-02-26
WO2013088243A1 (en)	2013-06-20
SMT201800664T1 (it)	2019-01-11
US9918978B2 (en)	2018-03-20
US20160256450A1 (en)	2016-09-08
US9498474B2 (en)	2016-11-22
EA030609B1 (ru)	2018-08-31
US10188643B2 (en)	2019-01-29
EP2790702A1 (en)	2014-10-22
IL232785B (en)	2021-04-29
HUE041883T2 (hu)	2019-06-28
PL3153171T3 (pl)	2019-02-28
US20180078542A1 (en)	2018-03-22
CA2858812A1 (en)	2013-06-20
AU2012351806A1 (en)	2014-05-15
US9913837B2 (en)	2018-03-13
EA201491153A1 (ru)	2015-04-30
EA030609B8 (ru)	2018-10-31
KR20140107258A (ko)	2014-09-04
JP6038170B2 (ja)	2016-12-07
ES2692771T3 (es)	2018-12-05
HRP20181950T1 (hr)	2019-03-22
US20150051240A1 (en)	2015-02-19
IL232785A0 (en)	2014-07-31
US20130190342A1 (en)	2013-07-25
KR101996108B1 (ko)	2019-10-01
CN106727562B (zh)	2019-07-05
EP3415148A1 (en)	2018-12-19
LT3153171T (lt)	2018-12-10
AU2012351806C1 (en)	2016-06-16
ES2791764T3 (es)	2020-11-05
US20210196703A1 (en)	2021-07-01
US10806731B2 (en)	2020-10-20
EP2790702B1 (en)	2020-04-01
US20190247387A1 (en)	2019-08-15
NZ624056A (en)	2016-07-29
US10314838B2 (en)	2019-06-11
BR112014012409B1 (pt)	2022-08-23
PT3153171T (pt)	2018-11-16
ZA201405029B (en)	2015-10-28
US8822488B2 (en)	2014-09-02

Publication	Publication Date	Title
BR112014012409A2 (pt)	2017-06-13	composições de buprenorfina e antagonistas do receptor mu-opiódie
ZA201307115B (en)	2014-05-28	Androgen receptor antagonists and uses thereof
SMT201600458B (it)	2017-03-08	Composizioni comprendenti buprenorfina
PL2927224T3 (pl)	2019-03-29	Antagoniści receptora
DK2821407T3 (da)	2017-01-02	Piperidinoncarboxamidazaindan-cgrp receptorantagonister
HK1252279A1 (zh)	2019-05-24	5- ht3受體拮抗劑
EP2665707A4 (en)	2015-01-14	ANTAGONISTS OF THE MINERALOCORTICOID RECEPTOR
ZA201308702B (en)	2015-02-25	Antagonists of cb1 receptor
HUE039607T2 (hu)	2019-01-28	Progeszteron antagonisták
HK1192228A1 (zh)	2014-08-15	受體拮抗劑
EP2697203A4 (en)	2014-10-15	Mineralocorticoid receptor antagonists
EP2765859A4 (en)	2015-03-18	Mineralocorticoid receptor antagonists
EP2539706A4 (en)	2013-07-31	ARYLPIPERAZON-OPIOID RECEPTOR ANTAGONISTS
BR112015005750A2 (pt)	2017-12-12	antagonistas peptídicos do receptor de vasopressina-2
EP2776064A4 (en)	2015-08-05	ANTAGONISTS OF PRO-VASOPRESSIN AND USES THEREOF
GB201213698D0 (en)	2012-09-12	Receptor antagonists II
GB201213699D0 (en)	2012-09-12	Receptor antagonists II

Legal Events

Date	Code	Title	Description
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-27	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-06-04	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-11-03	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-06-21	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-08-23	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2012, OBSERVADAS AS CONDICOES LEGAIS
2022-09-13	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REF. RPI 2694 DE 23/08/2022 QUANTO AO TITULO.
2024-10-08	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 12A ANUIDADE.
2025-02-04	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2805 DE 08-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.